Mini review highlights Nipah virus outbreaks and high case-fatality rate in South Asia, suggesting urgent therapeutic research.
Nipah virus (Niv), a zoonotic paramyxovirus of the Henipaviral genus, continues to pose recurrent epidemic threats across South and Southeast Asia. Initially recognized in Malaysia (1998–99) and later established as endemic in Bangladesh and India, its high case-fatality rate (40–90%) and absence of licensed therapeutics make it a pathogen of pandemic concern. Recent outbreaks in Kerala during 2018, 2021, and 2023 reaffirm the need for an integrated One Health approach, cross-border surveillance, and accelerated therapeutic research.
No takes yet. Share an insight, caveat, or question.
Kamalakar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: